ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc (LIPO)

0.4179
0.016
(3.98%)
終了 10月14日 5:00AM
0.4179
0.00
(0.00%)
取引時間後: 8:54AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
0.4179
買値
0.4126
売値
0.4173
出来高
90,562
0.40 日の範囲 0.4194
0.3234 52 週間の範囲 2.71
時価総額
前日終値
0.4019
始値
0.4018
最終取引時間
財務取引量
US$ 36,991
VWAP
0.408462
平均取引量 (3 か月)
3,919,208
発行済株式数
8,004,636
配当利回り
-
PER
-0.73
1 株当たり利益 (EPS)
-0.58
歳入
450k
純利益
-4.62M

Lipella Pharmaceuticals Inc について

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Lipella Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker LIPO. The last closing price for Lipella Pharmaceuticals was US$0.40. Over the last year, Lipella Pharmaceuticals shares have traded in a share price range of US$ 0.3234 to US$ 2.71.

Lipella Pharmaceuticals currently has 8,004,636 shares in issue. The market capitalisation of Lipella Pharmaceuticals is US$3.22 million. Lipella Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.73.

LIPO 最新ニュース

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc...

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York...

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study...

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancerNovel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
10.02376.012176560120.39420.43780.391779590.41242548CS
4-0.0172-3.953114226610.43510.530.37758234810.44356784CS
12-0.06-12.55492780920.47791.50.323439192080.84478406CS
26-0.2981-41.63407821230.7161.50.323418421150.84199525CS
52-0.5421-56.468750.962.710.323411381931.0522153CS
156-6.6021-94.0470085477.027.720.32347711941.39771784CS
260-6.6021-94.0470085477.027.720.32347711941.39771784CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
CAMPCAMP4 Therapeutics Corporation
 10.75
(2,587.50%)
378.47k
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M
NIVFNewGenIvf Group Ltd
US$ 0.98
(63.42%)
58.51M
ATIFATIF Holdings Ltd
US$ 1.235
(58.33%)
3.85M
VERBVerb Technology Company Inc
US$ 7.91
(51.82%)
15.55M
BYUBAIYU Holdings Inc
US$ 0.299
(-35.28%)
11.11M
TURBTurbo Energy SA
US$ 2.1511
(-29.01%)
3.2M
SMSTDefiance Daily Target 1.5X Short MSTR ETF
US$ 7.898
(-23.62%)
993.33k
VEEAVeea Inc
US$ 3.27
(-23.24%)
284.95k
INHDInno Holdings Inc
US$ 3.74
(-22.41%)
257.75k
JTAIJet AI Inc
US$ 0.1009
(23.50%)
340.09M
CDTConduit Pharmaceuticals Inc
US$ 0.116
(13.28%)
270.97M
NVDANVIDIA Corporation
US$ 134.80
(-0.01%)
170.27M
LUXHLuxUrban Hotels Inc
US$ 0.0532
(5.35%)
165.94M
TWGTop Wealth Group Holding Ltd
US$ 7.14
(233.64%)
154.23M

LIPO Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock